Protagonist Weaves Positive Story From Mixed Phase II Data In Ulcerative Colitis
Executive Summary
The company is pushing ahead into Phase III development with the lower dose of an oral drug for ulcerative colitis, even though a Phase II study missed the primary endpoint.
You may also be interested in...
Takeda Raises Full-Year Outlook On Strong Mainstays
Japan's largest pharma firm logs what was generally viewed by analysts as a solid fiscal third quarter, driven by growth for its portfolio of global products, leading to raised guidance for the full year despite one pipeline setback. There will also be multiple C-suite reshuffles come 1 April.
Radius Business Review Ends In Sale To Investment Funds
Gurnet Point Capital and Patient Square Capital will buy Radius Health for approximately $890m, including a contingent value right dependent on sales growth for osteoporosis drug Tymlos.
What Sanofi Early Research Chief Scientist Frank Nestle Is Most Excited About
Sanofi's Nestle talked to In Vivo about the company's early pipeline, the emerging technologies he thinks are most promising, and tapping external innovation.